Dustri Online Services

Books: 234	Journals: 18	Articles: 21295

Abstract

OSA, Gehirnfunktion und Gedächtnisstörungen – OSA, Schlaflosigkeit und Gedächtnisstörungen – Patienten mit OSA haben serologische Marker einer Nierenschädigung – Schlaf und Konsum von Milchprodukten – Zusam

Abstract

DGSM-Kongress 2025: OSA-Therapie sollte mehr können als nur „weniger Schläfrigkeit“!

Abstract

Nachrichten aus der NVSM: Frühjahr 2026

Abstract

Daridorexant: Verbesserte Schlafparameter auch bei psychiatrischen und neurologischen Komorbiditäten

Abstract

Verdauungskrankheiten, Jahrgang 44, Nr. 3/2026, S. 121-122

Editorial

A. Hörning

Abstract

Verdauungskrankheiten, Jahrgang 44, Nr. 3/2026, S. 123-134

Zöliakie – Klinik, Diagnostik und aktuelles zur Therapie

M.W. Laaß und Y. Zeißig

Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden
Die Zöliakie ist eine chronische Erkrankung des Dünndarms, die durch den Verzehr von Gluten und verwandten Proteinen bei genetisch veranlagten Personen ausgelöst wird und zu einer Zottenatrophie mit allen ihren Folgen führt. In Europa sind ca. 1% der Bevölkerung betroffen, Mädchen häufiger als Jungen. Die Symptomatik ist sehr variabel und viele extraintestinale Manifestationen können vorkommen. Für die primäre Diagnostik sollten IgA-Antikörper gegen Gewebstransglutaminase und das Gesamt-IgA bestimmt werden. In bestimmten Fällen kann bei Kindern auf eine Dünndarmbiopsie verzichtet werden. Die Diagnosestellung muss unter glutenhaltiger Ernährung erfolgen. Die Therapie besteht in einer lebenslangen, strikt glutenfreien Diät.Correspondence to:
Dr. med. Martin Laaß
Klinik und Poliklinik für Kinder- und Jugendmedizin
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
Fetscherstraße 74
01307 Dresden
Email: [email protected]

Abstract

Verdauungskrankheiten, Jahrgang 44, Nr. 3/2026, S. 135-146

Chronisch-entzündliche Darmerkrankungen bei Kindern und Jugendlichen – aktuelle Konzepte in Diagnostik, Therapie und Versorgung

J. de Laffolie

Abteilung für Allgemeine Pädiatrie und Neonatologie, Kinderklinik des UKGM am Standort Gießen, Gießen
Chronisch-entzündliche Darmerkrankungen (CED) wie Morbus Crohn und Colitis ulcerosa manifestieren sich bei etwa 25% der Betroffenen bereits im Kindes- oder Jugendalter. Der pädiatrische Krankheitsverlauf unterscheidet sich teils deutlich von dem Erwachsener und ist oft durch eine ausgeprägtere Entzündung, Wachstumsverzögerung und extraintestinale Manifestationen geprägt. Die aktuelle Versorgung orientiert sich an internationalen Leitlinien und umfasst individualisierte Therapieziele (STRIDE-II), neue Bildgebungsverfahren sowie den frühen Einsatz von Biologika. Der Beitrag fasst wesentliche Aspekte der Pathogenese, Klinik, Diagnostik und Therapie zusammen und geht auf besondere Herausforderungen wie akut schwere Colitis ulcerosa und Very Early Onset IBD (VEO-IBD) ein. Monitoringstrategien, Off-Label-Therapien sowie psychosoziale Aspekte werden praxisnah dargestellt.Correspondence to:
Prof. Dr. med. Jan de Laffolie
Abteilung für Allgemeine Pädiatrie und Neonatologie
Kinderklinik des UKGM am Standort Gießen
Feulgenstraße 10-12
35392 Gießen
Email: [email protected]

Abstract

Verdauungskrankheiten, Jahrgang 44, Nr. 3/2026, S. 147-154

Heimparenterale Ernährung bei Kindern mit chronischem Darmversagen

F. Lang¹#², J. Garino³, A. Rückel⁴, D. Vermeulen¹, I. Tsiflikas⁵ und J. Hilberath¹

¹Universitätsklinik Tübingen, Klinik für Kinder- und Jugendmedizin, Abteilung I, Pädiatrische Gastroenterologie und Hepatologie, ²Fachpflege für Intestinale Rehabilitation, Pflegewissenschaftlerin BScN, Advanced Practice Nurse stud. MSc ANP, ³Ernährungswissenschaftlerin, Garino Medical Consulting, Nidda, ⁴Universitätsklinikum Erlangen, Kinder- und Jugendklinik, Pädiatrische Gastroenterologie, ⁵Universitätsklinikum Tübingen, Abteilung Diagnostische und Interventionelle Radiologie, Kinderradiologie
Kinder mit chronischem Darmversagen können über Jahre bis lebenslang abhängig von heimparenteraler Ernährung über zentralvenöse Langzeitkatheter sein, um Überleben, Wachstum und Entwicklung zu gewährleisten. Die Grundsätze dieser Ernährungsform werden in diesem Artikel vorgestellt. Zusammensetzung und Applikation der parenteralen Ernährung richten sich nach den individuellen Bedürfnissen, den (anatomischen) Voraussetzungen und den Ergebnissen einer sorgfältigen Überwachung. Die interdisziplinäre Betreuung gemäß den Konzepten der intestinalen Rehabilitationsprogramme können Komplikationen wie katheterassoziierte Infektionen, Gefäßzugangsverluste und chronische Hepatopathie reduzieren sowie die Lebensqualität betroffener Kinder und Jugendlicher verbessern. So können durch Modifizierung des Ernährungsregimes und spezifische Pflegetechniken nicht nur Endorganschäden reduziert, sondern auch Pausenzeiten für eine infusionsfreie und aktive Alltagsgestaltung ermöglicht werden.Correspondence to:
Dr. med. Johannes Hilberath
Universitätsklinik Tübingen
Klinik für Kinder- und Jugendmedizin
Abteilung I, Pädiatrische Gastroenterologie und Hepatologie
Hoppe-Seyler-Str. 1
72076 Tübingen
Email: [email protected]

Abstract

Verdauungskrankheiten, Jahrgang 44, Nr. 3/2026, S. 155-165

Cholestatische Lebererkrankungen im Kindes- und Jugendalter

F. Mutschler und E.-D. Pfister

Kinderklinik der Medizinischen Hochschule Hannover, Klinik für Päd. Nieren-, Leber- und Stoffwechselerkrankungen, Pädiatrische Gastroenterologie, Hepatologie und Lebertransplantation
Cholestatische Lebererkrankungen sind eine heterogene Gruppe von Erkrankungen unterschiedlicher Ätiologie, die mit einem Rückstau von Bilirubin, Gallensäuren oder anderen Gallebestandteilen durch verminderten, fehlenden oder fehlerhaften Abfluss von Galle in den Darm einhergehen oder durch eine veränderte Zusammensetzung der Galle charakterisiert sind. Die Ursachen sind vielfältig und können angeboren oder erworben sein. In der Folge resultiert eine hepatozelluläre Schädigung und/oder obstruktive bzw. nicht obstruktive Cholestase. Cholestatische Lebererkrankungen im Kindesalter verlaufen oft chronisch und gehen mit unterschiedlichen Komplikationen und Auswirkungen auf die Entwicklung, Lebensqualität, Morbidität und Mortalität einher. Ikterus, Juckreiz, Malnutrition sowie Mangelsymptome fettlöslicher Vitamine stehen klinisch oft im Vordergrund, laborchemisch führend ist eine direkte Hyperbilirubinämie. Die Behandlung erfolgt falls möglich kausal, je nach Erkrankung stehen medikamentöse und operative Maßnahmen zur Verfügung. Die Basis jeder Therapie ist die symptomorientierte Behandlung, hierbei nimmt die Ernährungsintervention eine entscheidende Rolle ein. Eine Lebertransplantation ist in vielen Fällen die einzige lebensrettende Option.Correspondence to:
Dr. med. Frauke Mutschler
Medizinische Hochschule Hannover
Pädiatrische Gastroenterologie, Hepatologie und Lebertransplantation
Carl-Neuberg-Str. 1
30625 Hannover
Email: [email protected]

Abstract

Verdauungskrankheiten, Jahrgang 44, Nr. 3/2026, S. 166-172

Eosinophile gastrointestinale Erkrankungen (EGID)

H. Hölz¹ und T. Schwerd¹#²

¹Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, Abteilung für pädiatrische Gastroenterologie, Hepatologie und Ernährung, Klinikum der Ludwig-Maximilians-Universität München (LMU), München, ²Sektion Kindergastroenterologie, Klinikum Dritter Orden München-Nymphenburg, München
Während zur eosinophilen Ösophagitis (EoE) nach jahrzehntelanger Forschung umfassende Leitlinien existieren, gibt es für andere eosinophile gastrointestinale Erkrankungen (engl. Eosinophilic Gastrointestinal Disorders, EGIDs) bislang nur begrenzte Empfehlungen. Wegen der zunehmenden Häufigkeit rücken die Definition, Diagnostik und der natürliche Verlauf der Non-EoE-EGIDs, wie eosinophiler Gastritis, Enteritis und Kolitis immer mehr in den Fokus. Ihre Diagnostik bleibt wegen Seltenheit und variabler Symptomatik herausfordernd, was zu Diagnoseverzögerungen und Einschränkungen der Lebensqualität führen kann. Erste Leitlinien zur histologischen Beurteilung und Diagnose liegen vor und ermöglichen heute bereits wirksame Therapien. Dennoch zeigen neue Therapieansätze, wie wichtig ein vertieftes pathophysiologisches Verständnis dieser Erkrankungen ist.Correspondence to:
PD Dr. med. Tobias Schwerd
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
Abteilung für pädiatrische Gastroenterologie, Hepatologie und Ernährung
Klinikum der Ludwig-Maximilians-Universität München (LMU)
Lindwurmstraße 4
80337 München
Email: [email protected]

Abstract

Verdauungskrankheiten, Jahrgang 44, Nr. 3/2026, S. 173-180

Industrienachrichten

Abstract

Allergologie select, Vol. 10/2026 (120-144)

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation

Thomas Werfel¹, Annice Heratizadeh¹, Matthias Augustin², Christine Bangert³, Andrea Bauer⁴, Tilo Biedermann⁵, Richard Brans⁶, Nadine Domröse¹, Uwe Gieler⁷, Oliver Gießler-Fichtner⁸, Eckard Hamelmann⁹, Selina Hampe¹⁰, Ruben Heuer¹¹, Julia Kahle¹⁰, Maria Kinberger¹¹, Markus Koch¹², Meike Köhler¹³, Franz Legat¹⁴, Katja Nemat¹⁵,¹⁶, Irena Neustädter¹⁷, Eva M. J. Peters¹⁸, Susanne Radonjic-Hoesli¹⁹, Imke Reese²⁰, Peter Schmid-Grendelmeier²¹, Uta-Katharina Schmidt-Göhrich²², Jochen Schmitt²³, Christina Schnopp⁵, Thomas Schwennesen²⁴, Dagmar Simon¹⁹, Kristina Stamos¹⁶, Christian Termeer²⁵,²⁶, Regina Treudler²⁷, Ralph von Kiedrowski²⁸, Iris Wagner²⁴, Anja Waßmann-Otto²⁹, Gesine Weckmann³⁰, Ricardo Niklas Werner¹¹, Andreas Wollenberg³¹,³², Margitta Worm³³, and Hagen Ott¹³,³⁴

¹Department of Dermatology and Allergy, Hannover Medical School, Hannover, ²Competence Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ³Department of Dermatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, ⁵TUM University Hospital, Department of Dermatology and Allergy, Munich, ⁶Institute for Interdisciplinary Dermatological Prevention and Rehabilitation (iDerm) at the Osnabrück University, Osnabrück, ⁷Department of Psychosomatic Medicine and Psychotherapy, University Hospital Gießen, Gießen, ⁸Gaißach Specialist Clinic of DRV Bayern Süd, Gaißach, ⁹Children’s Center, Evangelical Hospital Bethel, University Hospital OWL, University of Bielefeld, Bielefeld, ¹⁰German Allergy and Asthma Association (DAAB), Mönchengladbach, ¹¹Department of Dermatology, Venereology and Allergology, Division of Evidence Based Medicine in Dermatology (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, ¹²Alpenklinik Santa Maria, Bad Hindelang, ¹³Section for Integrated Pediatric Dermatology (iKinD), Munich Center for Children with Medical and Developmental Complexity, LMU University Hospital, Munich, Germany, ¹⁴Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria, ¹⁵Practice for pediatric pneumology and allergology, Children’s Center Dresden-Friedrichstadt (Kid), ¹⁶Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, ¹⁷Hospital Hallerwiese, Cnopfsche Kinderklinik, Nuremberg, ¹⁸Psychoneuroimmunology Laboratory, Department of Psychosomatic Medicine and Psychotherapy, Justus-Liebig University Gießen, Gießen, Germany, ¹⁹Department of Dermatology, Inselspital Bern, Bern, Switzerland, ²⁰Private Practice for Dietary Advice and Nutrition Therapy with Special Interest in Adverse Reactions to Food, Munich, Germany, ²¹Allergy Unit, Department of Dermatology, University Hospital Zurich and Christine Kuehne Center for Allergy Research and Education CK-CARE Davos, Switzerland, ²² Carus Family Practice at Dresden University Hospital, ²³Center for Evidence-Based Healthcare (ZEGV), University Hospital Dresden and Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, ²⁴German Eczema Association (DNB), Hamburg, ²⁵Dermatology Practice at Löwenmarkt, Stuttgart-Weilimdorf, ²⁶Department of Dermatology, University-Hospital Freiburg, Freiburg, ²⁷Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, ²⁸Selters Dermatology Practice, Selters, ²⁹Mensing Derma MVZ, Hamburg, ³⁰Weckmann Institute of Medical and Healthcare Education, Rostock, ³¹Department of Dermatology and Allergology, University Hospital Augsburg, Augsburg, ³²Clinic and Polyclinic for Dermatology and Allergology, Ludwig Maximilian University, Munich, ³³Department of Dermatology, Venereology, and Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, and ³⁴Department of Pediatric Surgery, Dr. Von Hauner Children’s Hospital, LMU University Hospital, Munich, Germany
This guideline is a partial update of the S3 guideline on atopic dermatitis (AWMF register no. 013-027) published in 2023. The chapters on systemic therapy with biologics and Janus kinase inhibitors as well as the chapter on pregnancy, breastfeeding and family planning in the context of systemic therapies for atopic dermatitis have been updated. This was prompted by new approvals (lebrikizumab, nemolizumab), approval extensions (abrocitinib from 12 years of age, baricitinib from 2 years of age) and new evidence on the use of biologics before and during pregnancy. In addition, a new chapter on treatment goals, treatment expectations and criteria for treatment adjustment (“treat-to-target”) in systemic therapies has been added to the guideline. This article only presents the updated and newly added chapters. The complete guideline is available on the AWMF website.Correspondence to:
PD Dr. Annice Heratizadeh, Department of Dermatology and Allergy, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
Email: [email protected]

Abstract

Clinical Neuropathology, Vol. 45 – No. 3/2026 (86-97)

From genes to neuropathology: Integrative perspectives on the spectrum of spinocerebellar ataxias

Jeroen J. de Vries¹, Maria João da Costa Caiado²#³, and Wilfred F.A. den Dunnen²

¹Expertise Center for Movement Disorders, Department of Neurology, ²Department of Pathology and Medical Biology, Division of Pathology, University Medical Center Groningen, and ³Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
This review describes the clinically and genetically heterogenous group of 52 Spinocerebellar ataxias (SCAs). After a brief description of the epidemiology and clinical spectrum, this review highlights the functional neuroanatomy, the need for sufficient sampling based on this knowledge, and showcases examples of neuropathology. In addition, a comprehensive overview of the pathogenesis of the different forms of spinocerebellar ataxias (SCAs) is given.Correspondence to:
Wilfred F.A. den Dunnen, MD, PhD,
Associate Professor in Neuropathology
Department Pathology and Medical Biology
University Medical Center Groningen
PO Box 30.001
9700 RB Groningen, The Netherlands
Email: [email protected]

Abstract

Pan Lu¹, Fang Yao¹, Jie Wang¹, Yingxia He¹, Jun Liang¹, Xuejia Zhai²,³, and Guan Liu¹

¹PhaseI Clinical Research Center, Wuhan Pulmonary Hospital, ²Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and ³Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Union Hospital, Wuhan, China
Apremilast is a pioneering oral selective phosphodiesterase-4 inhibitor for the treatment of psoriasis. To evaluate and compare the pharmacokinetic properties and bioavailability of apremilast tablets manufactured by Nanjing Haijing Pharmaceutical Company (Nanjing, China) with apremilast tablets certified by Celgene Europe B.V. (Utrecht, The Netherlands), we conducted a randomized, open-label, single-dose, two-period, crossover study in healthy Chinese subjects under fasted and fed conditions. Eligible subjects were randomly assigned to receive reference or test apremilast tablets in the first treatment period and the other formulation in the second period. Serial blood samples were collected for pharmacokinetic analysis. Adverse events were recorded. A total of 28 healthy subjects were enrolled in the fasting cohort and 36 subjects in the fed cohort. The 90% confidence intervals of the geometric mean ratios of the test to reference formulations were 91.56 – 106.18% for Cmax, 96.08 – 108.18% for AUC0–t, and 96.02 – 107.67% for AUC0–∞ in the fasting cohort, and 95.15 – 107.05% for Cmax, 105.13 – 113.45% for AUC0–t, and 104.80 – 111.91% for AUC0–∞in the fed cohort, all of which were within the bioequivalence range of 80.00 – 125.00%. There were no serious adverse events. The results showed that the test and reference apremilast tablets were bioequivalent and well tolerated in healthy Chinese subjects under fasting and fed conditions. Correspondence to:
Guan Liu, MD, Phase|Clinical Research Center, Wuhan Pulmonary Hospital, Wuhan, People’s Republic of China
Email: [email protected]

Abstract

Li-Wen Zhang¹, An Huang², Hong-Fang Ma³, and Jun Shen¹

¹Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou City, ²Department of Breast Surgery, Maternal and Child Health Hospital, Yiwu City, and ³Department of Plastic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
Objective: Through a network meta-analysis, this study aimed to systematically evaluate the efficacy and safety of bisphosphonates in reducing skeletal-related events in patients with bone metastases from breast cancer, providing clinical guidance for treatment selection. Materials and methods: Randomized controlled trials (RCTs) on bisphosphonate therapy for bone metastases in breast cancer were retrieved from PubMed, Cochrane, and Embase databases from inception to January 2025. Statistical analyses were performed using Stata software. Results: 22 studies involving 14,934 patients were included. The bisphosphonates evaluated were pamidronate, zoledronate, clodronate, and ibandronate. Regarding the reduction of pathological fractures, the efficacy ranking was clodronate > ibandronate > pamidronate > zoledronate. Significant differences were found between clodronate and pamidronate (OR = –1.41, 95% CI: –2.78 to –0.04) and between clodronate and zoledronate (OR = –1.44, 95% CI: –2.85 to –0.04). For hypercalcemia reduction, zoledronate was more effective than clodronate and pamidronate, though differences were not statistically significant (p > 0.05). In terms of safety, ibandronate showed fewer adverse reactions than clodronate and zoledronate, with a significant difference between ibandronate and zoledronate (OR = –1.14, 95% CI: –1.99 to –0.28). Conclusion: Clodronate was most effective in reducing pathological fractures, zoledronate was superior in controlling hypercalcemia, and ibandronate demonstrated the best safety profile. Further clinical studies are warranted to clarify the comparative advantages of each bisphosphonate and support individualized treatment decisions. Correspondence to:
Jun Shen, MD, Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3. East road of Qingchun, Hangzhou 310016, Zhejiang Province, China
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 64 – No. 8/2026 (416-427)

Novel intravenous human IVIG in patients with secondary immunodeficiency: Interim analysis of a multicenter, prospective, non-interventional study 

Artur Bauhofer¹, Silke Aigner¹, and Stephan Borte²

¹Biotest, Dreieich, and ²Immune Defect Center, Clinic St. Georg, Leipzig, Germany
Objective: To evaluate the effectiveness, safety, and tolerability of Yimmug, a novel, highly purified, 10% human plasma-based intravenous immunoglobulin (IVIG) preparation, in patients with secondary immunodeficiency (SID) under real-world conditions.
Materials and methods: This interim analysis is based on data from a multicenter, prospective, non-interventional study conducted with out-patients in Germany. Effectiveness was assessed by changes in (i) serum IgG levels, (ii) severe infection rates, (iii) clinical symptoms, and (iv) patient-reported quality of life (QoL) at three treatment intervals (after 3, 12, and 24 IVIG infusions) compared to baseline. Safety was evaluated through documentation of adverse events (AEs), including adverse drug reactions (ADRs), while tolerability was assessed by investigators.
Results: A total of 119 SID patients received 726 IVIG infusions at a median (IQR) dose of 0.3 (0.2 – 0.3) g/kg over a median (IQR) duration of 1.4 (0.4 – 2.9) years, with a median interval of 30.1 days between infusions. Serum IgG trough levels increased, with the proportion of patients achieving IgG ≥ 6 g/L rising from 30.3% at baseline to 66.7% after both 12 and 24 infusions. The mean annual rate of infections requiring antibiotics decreased from 2.3 at baseline to 0.0 after 3 and 12, and to 0.4 after 24 infusions, respectively. The new IVIG was well tolerated, and patients’ clinical symptoms and QoL improved during treatment. AEs were reported in 20 (16.8%) patients, with 41 events in total, while ADRs occurred in 9 (7.6%) patients, with 16 events. Serious AEs (SAEs) occurred in 4 (3.4%) patients, involving 5 events, but no serious ADRs (SADRs) were reported.
Conclusion: This interim analysis shows that the risks are minor compared to the benefits of this novel IVIG preparation in the management of SID.Correspondence to:
Prof. Dr. Artur Bauhofer
Biotest
Landsteinerstr. 5
63303 Dreieich, Germany
Email: [email protected]

Abstract

Jeroen J. de Vries¹, Maria João da Costa Caiado²,³, and Wilfred F.A. den Dunnen²

¹Expertise Center for Movement Disorders, Department of Neurology, ²Department of Pathology and Medical Biology, Division of Pathology, University Medical Center Groningen, and ³Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
Background: Episodic ataxias (EAs) are rare autosomal-dominant channelopathies presenting with recurrent attacks of ataxia and variable neurological features. While MRI studies suggest mild cerebellar atrophy in some patients, detailed neuropathological descriptions are lacking. Materials and methods: We examined postmortem brains and spinal cords from two genetically confirmed patients: EA1 (KCNA1 Val174Phe mutation) and EA2 (CACNA1A A253Y mutation). Routine histology and immunohistochemistry were performed. Results: In EA1, the cerebellar vermis and hemispheres showed narrowing of the folia, segmental Purkinje cell loss, Bergmann gliosis, and scattered torpedoes. The dentate nucleus contained focal lipofuscin-laden macrophages and Rosenthal fibers. Concurrently, α-synuclein pathology (Braak stage 3) was also present, along with sparse age-related tau tangles and minimal vascular amyloid. In EA2, only focal Purkinje cell loss was detected, but novel p62-positive axonal and dendritic inclusions were observed in the cerebellar cortex and inferior olive. No additional α-synuclein, tau, or amyloid pathology was found. A concurrent glioblastoma was identified as the immediate cause of death. Conclusion: These are the first detailed autopsy reports of EA1 and EA2. Both revealed cerebellar pathology, with EA1 showing more pronounced Purkinje cell degeneration, while EA2 demonstrated previously undescribed p62-positive inclusions. These findings expand the clinicopathological spectrum of EAs and highlight the value of postmortem studies in elucidating underlying disease mechanisms.Correspondence to:
Wilfred F.A. den Dunnen, MD, PhD, Associate Professor in Neuropathology, Department Pathology and Medical Biology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
Email: [email protected]

Abstract

Allergologie select, Vol. 10/2026 (114-119)

Resolution of childhood wheat allergy through evolution into WALDA? A case report

Charlotte J. Kiani¹, Valentina Faihs¹, Claudia Kugler¹, Julia F. Pilz¹, Tilo Biedermann¹, and Knut Brockow¹,²

¹Department of Dermatology and Allergy, Technical University of Munich, TUM School of Medicine and Health, Munich, Germany, and ²Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
Background: Wheat allergy may present with different phenotypes. Childhood-onset wheat allergy is characterized by immediate-type IgE-mediated reactions to wheat ingestion alone. It typically affects atopic individuals and often resolves spontaneously. The predominant adult-onset phenotype is WALDA (wheat allergy dependent on augmentation factors), triggered only when wheat is consumed in combination with augmentation factors. Phenotypic transition between these forms is rarely described. Case report: We present the case of a 30-year-old atopic female patient with a history of wheat-induced anaphylaxis, who presented with three distinct stages, compatible with a phenotypic transition. In infancy, the patient was diagnosed with classical IgE-mediated wheat allergy. In early adulthood, she developed augmentation factor-dependent reactions compatible with WALDA. At the age of 30, comprehensive oral food challenge testing and serological analysis revealed full clinical tolerance and loss of sensitization. Conclusion: This case illustrates a possible transient clinical course of wheat allergy with WALDA as an intermediate stage prior to resolution. Such cases may be underreported, as patients with declining wheat allergy may not be identified as having WALDA reactions, but rather as having inconstant reactivity. Allergy reassessment in adult patients with food allergy in childhood is essential to detect phenotypic shifts or to confirm resolution.Correspondence to:
Dr. med. Valentina Faihs, Department of Dermatology and Allergy, Technical University of Munich, TUM School of Medicine and Health, Biedersteiner Str. 29, 80802 Munich, Germany
Email: [email protected]

Abstract

Allergologie select, Vol. 10/2026 (151-157)

In vitro IgE diagnostics in inhalant allergy: Plant and mold allergens

Regina Treudler

Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Respiratory allergies represent one of the most prevalent immune-mediated disorders worldwide, such as allergic rhinitis and asthma. The advent of in vitro diagnostic methods, particularly those based on molecular allergology, has revolutionized the diagnostic approach to inhalant allergies by enabling precise identification of sensitizing allergens at the molecular level. This review presents an analysis of the current status of in vitro diagnostics in respiratory allergy to plants and molds, with emphasis on molecular diagnostics for key allergens from trees (e.g., birch/Betula verrucosa), grasses (Poaceae family), weeds (e.g.mugwort/Artemisia vulgaris, ragweed/Ambrosia artemisiifolia), and molds (e.g. Alternaria, Aspergillus). We discuss major allergenic proteins, diagnostic tools, implications for precision medicine, and integration with precision immunotherapy.Correspondence to:
Prof. Dr. Regina Treudler, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Haus 2, Institute of Allergology, Hindenburgdamm 30, 12203 Berlin, Germany
Email: [email protected]

Abstract

Allergologie select, Vol. 10/2026 (145-150)

Contact allergy to a titanium port catheter: Diagnostic challenges and clinical resolution

Silas Fugger¹, Alexander Kauffmann², and Heinrich Dickel¹

¹Department of Dermatology, Venereology and Allergology, St. Josef Hospital, University Medical Center, Bochum, and ²Chair for Materials Science and Engineering, Institute for Materials, Faculty of Mechanical Engineering, Ruhr University Bochum, Bochum, Germany
Background: Titanium and its alloys are widely used in modern medical devices because of their favorable biocompatibility and mechanical properties. Allergic reactions to titanium-based implants are considered rare, and their diagnosis is hampered by the poor dermal penetration of metallic allergens. Case report: A 29-year-old female patient with seronegative myasthenia gravis requiring parenteral nutrition presented with persistent inflammatory dermatitis overlying a titanium port catheter (X-Port BARD Titan low-profile) 4 weeks after implantation in July 2023. Despite initial diagnostic uncertainty and sequential management modifications, her condition continued to deteriorate. Similar eruptions developed after re-implantation of the same titanium port model on the contralateral thorax. Rigorous patch testing incorporating standardized tape-stripping and extended reading intervals revealed positive sensitization to the titanium port body, while all other port components and an alternative plastic port system (BARD SlimPort M.R.I. Ultra Low-Profile) tested negative. Energy-dispersive X-ray spectroscopy confirmed the titanium body composition as a Ti-Al6-V4 alloy. Substitution with the plastic port catheter in February 2025 resulted in complete symptom resolution, with sustained clinical remission through July 2025. Conclusion: Although very uncommon, contact sensitization to titanium medical devices can occur and may present significant diagnostic and therapeutic challenges. Rigorous patch testing methodology, incorporating standardized tape-stripping and extended 168-hour readings, appears essential for detecting delayed-type hypersensitivity to metallic implants. Clinical resolution following biocompatible device substitution supports an allergic etiology in this case.Correspondence to:
Silas Fugger, Department of Dermatology, Venereology and Allergology, Ruhr University Bochum, Gudrunstraße 56, 44791 Bochum, Germany
Email: [email protected]

Warenkorb Übersicht
Typ	Anz	Rabatt	MwSt	Preis
Der Warenkorb ist leer

Ihr Warenkorb

Atemwegs- und Lungenkrankheiten

Search Results

Warenkorb Übersicht

Atemwegs- und Lungenkrankheiten

Search Results

Warenkorb Übersicht

Senden Sie uns eine E-Mail